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Abstract 30 
 31 
The neurotransmitter serotonin has a role in affective disorders such as depression and anxiety, as 32 
well as sleep, cognitive function and appetite. This review examines the evidence that serotonin-33 
related genotypes may moderate the behavioural effects of supplementation with the serotonin 34 
precursor amino acid tryptophan (TRP), on which synthesis of serotonin (or 5-hydroxytryptamine; 35 
5-HT) depends.  However, 95% of serotonin is synthesised and used in the periphery, and TRP is 36 
also metabolised via non-5-HT routes such as the kynurenine pathway.  Moreover, understanding of 37 
genotypes involved in regulation of serotonin raises questions over the generalisability of TRP 38 
effects on behaviour across individuals with varied serotonergic genotypes. To date, only 39 
differences between variants of the 5-HT transporter-linked promoter region (5-HTTLPR) have 40 
been investigated in relation to behavioural effects of TRP supplementation. Effects of 5-HTTLPR 41 
genotypes are usually compared between the alleles that are either high (L/L’) or low (S/S’) 42 
expressing of mRNA for the 5-HT transporter receptor.   Yet, another key genetic variable is sex:  43 
in women, the S/S’ genotype predicts sensitivity to improved mood and reduced cortisol by TRP 44 
supplementation, during stressful challenges, whereas the L/L’ genotype protects against stress-45 
induced mood deterioration.  In men, the L/L’ genotype may confer risk of stress-induced increases 46 
in negative affect; there are insufficient data to assess effects in male S/S’ genotypes.  However, 47 
better powered studies to detect sex by genotype by stress by TRP interactions, as well as 48 
consideration of more genotypes, are needed before strong conclusions and recommendations for 49 
behavioural effects of TRP treatment can be reached. 50 
 51 
  52 
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Dietary tryptophan and the pathways to serotonin function 53 
 54 
Serotonin, or 5-hydroxytryptamine (5-HT), is a monoamine neurotransmitter in the central 55 
nervous systems (CNS) of the majority of animals including human beings.  Its synthesis depends 56 
on supply of the essential amino acid, l-tryptophan (TRP), which cannot be biosynthesised by 57 
human beings and so must be obtained from dietary sources.  Moreover, serotonin synthesis rate 58 
depends on availability of the precursor TRP.  The scope of this review is to consider recent 59 
findings from research involving effects of supplementing TRP supply on behaviour and their 60 
interaction with genetic susceptibility, including indirect evidence that TRP supplementation likely 61 
alters affective states via effects on central serotonin function.   62 
An important consideration for understanding effects of TRP administration is that only 63 
about 5% of endogenous serotonin is found in the brain; the remainder is in the gut (about 90%), 64 
principally released by enterochromaffin cells, and in peripheral tissue or in the blood, where it is 65 
taken up into blood platelets (1; 2; 3). Indeed, the name serotonin derives from its discovery in blood 66 
70 years ago and the observation that it caused contraction of vascular smooth muscle (4); thus, one 67 
function of serotonin is to regulate local blood flow.  This imbalanced distribution between brain 68 
and periphery needs to be borne in mind when considering the possible impact of dietary 69 
manipulation of central serotonin by TRP, and the potential influence of alternative metabolic 70 
pathways as well as probable moderating effects on these metabolic routes.  These issues are 71 
considered further below; nevertheless, serotonin is a widely distributed and important CNS 72 
neurotransmitter, arising from neuronal cell bodies located in the higher and lower raphe nuclei of 73 
the brainstem, and acting at multiple receptor subtypes with a range of behavioural effects (5).   74 
Serotonin’s established importance in affective disorders and appetite, as well as sleep and 75 
cognition (6), make understanding who might benefit most from therapeutic use of TRP an important 76 
goal of research . 77 
Metabolic pathways for l-tryptophan 78 
 79 
As with other essential amino acids, TRP can contribute to hepatic biosynthesis of proteins; 80 
however, TRP is typically incorporated into proteins at only 1-2% of total amino acids, making it 81 
the scarcest of amino acids in dietary proteins (3; 7).  Nevertheless, if TRP is acutely deficient, 82 
incorporation into protein synthesis will contribute to a substantial lowering of plasma TRP levels 83 
(8; 9). However, in the absence of TRP deficiency, the majority of consumed TRP is metabolised via 84 
other pathways, including for synthesis of 5-HT, melatonin and niacin (vitamin B3).  Indeed, it has 85 
4 
 
been estimated that only 1% of dietary TRP is used for brain 5-HT synthesis (10).  TRP use for 86 
synthesis of niacin is via the oxidative kynurenine pathway, which has also been termed the 87 
‘tryptophan catabolite’ pathway (TRYCAT) (11).  This pathway is becoming increasingly recognised 88 
as having important implications for health, including neuropsychiatric conditions such as 89 
depression (11; 12). A further route for TRP metabolism is via degradation by gut microbiota, which 90 
can lead to production of both positive and detrimental active metabolites, including quinolinic acid 91 
(1); therefore, individual variation in the gut microbiome may have implications for TRP metabolism 92 
and thus brain health and psychological wellbeing (13).   93 
 The kynurenine, or TRYCAT, pathway involves an initial rate-limiting metabolism of TRP 94 
to kynurenine catalysed by the hepatic enzyme, tryptophan 2,3-dioxygenase (TDO), which can be 95 
induced by glucocorticoid hormones (14).  However, under inflammatory conditions, the extrahepatic 96 
enzyme, indole 2,3-dioxygenase (IDO) becomes increasingly important in metabolising TRP to 97 
kynurenine, due to induction by pro-inflammatory cytokines (11).  These inductive influences on 98 
diversion of TRP metabolism away from 5-HT synthesis have been proposed as mechanisms 99 
underlying the link between stress, inflammation, deficient 5-HT function and depression (11; 12). 100 
 The metabolism of TRP for synthesis of 5-HT is catalysed by the rate-limiting enzyme, 101 
tryptophan hydroxylase, which converts TRP into 5-hydroxytryptophan (5-HTP).  In turn, 5-HTP is 102 
decarboxylated to 5-HT by the enzyme aromatic amino acid decarboxylase.  The key observation 103 
for this pathway is that TRP hydroxylase (TPH) is not fully saturated by its substrate TRP under 104 
normal conditions, so that raising brain TRP levels could increase serotonin synthesis. However, 105 
brain TRP levels are buffered from plasma TRP by the blood brain barrier (BBB): to be transported 106 
into the brain, TRP has to compete for uptake across the BBB against other amino acids, in 107 
particular a group known as the large neutral amino acids (LNAA), especially the branched chain 108 
amino acids, leucine, isoleucine and valine, but also phenylalanine and tyrosine (the precursors for 109 
catecholamine – dopamine, adrenaline, noradrenaline - transmitter synthesis).  Thus, the ratio of 110 
plasma or serum TRP to LNAA (TRP/LNAA) is recognised as the best peripheral biomarker of 111 
uptake of TRP into the brain (7).  Some 90% of TRP in blood is typically bound to the blood protein 112 
albumin, and it is often assumed that the remaining free unbound fraction of TRP should be taken to 113 
be the best predictor of TRP entry across the BBB.  However, it has been shown that TRP binding 114 
to albumin is very labile, such that TRP can easily be released in cerebral circulation.  Furthermore, 115 
TRP can be displaced from or prevented from binding to albumin by free fatty acids (FFA), which 116 
also bind readily to albumin (7; 9).   Therefore, factors that alter FFA levels in blood will affect 117 
availability of free TRP for entry into the brain: for example, sympathetic activation by stress or 118 
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exercise will induce lipolysis, increase plasma FFA and so release more TRP from albumin.  This 119 
acute stress-induced increase in availability of TRP for serotonin synthesis might contribute to the 120 
observation that even mild stress can increase 5-HT release in rat brain (15).  It also suggests caution 121 
is required in interpreting correlations between single measures of plasma free TRP and personality 122 
traits such as anxiety or aggression, as these may interact with the experimental procedure and 123 
perceived stressful nature of the study to modify TRP levels.  In contrast, food or drink that 124 
stimulates insulin release, and so promotes uptake of FFA into tissue, will tend to reduce 125 
availability of free plasma TRP, but at the same time will remove competing LNAA from plasma 126 
into tissue (7).  Thus, measuring both free and total TRP may ensure better prediction of TRP entry 127 
into brain and its behavioural associations (9; 16). 128 
 However, 95% of 5-HT is synthesised and used in the gut, blood and peripheral tissue (1; 14).  129 
Although the synthesis of 5-HT from TRP follows a similar biochemical path in brain and 130 
periphery, the form of the enzyme TPH by and large differs slightly between these regions; these 131 
isoforms are known as TPH1 and TPH2 respectively, indicating the order of characterisation (17; 18).  132 
To be precise, in the brain the principal isoform, TPH2, shown to depend on expression of a 133 
different gene form from TPH1 (18), was found to be highly expressed by measuring mRNA specific 134 
to the brainstem raphe nuclei, where brain serotonin is primarily synthesised, whereas TPH1 was 135 
found to be responsible for 5-HT synthesis, and ultimately melatonin, in the pineal gland (19) and gut 136 
(18).  However, this classification is oversimplified, as TPH1 mRNA has also been shown to be more 137 
highly expressed in the amygdala and hypothalamus than TPH2 (20), although its precise role in 138 
those sites is uncertain.  139 
Serotonin and behaviour 140 
 141 
Serotonin has long been associated with several fundamental aspects of behaviour including 142 
sleep, appetite, cognition, and social and emotional behaviours such as anxiety, depression, 143 
empathy and aggression (21; 22).  These influences of serotonin on behaviour will be briefly reviewed 144 
prior to consideration of the impact of TRP supplementation and its interaction with 5-HT-related 145 
genotypes. 146 
Early neurophysiological and lesion work on the function of CNS 5-HT demonstrated a 147 
clear role in regulating sleep (23), whereas the therapeutic use of monoamine oxidase inhibitors 148 
(which prevent serotonin, and other monoamine, metabolism by the enzyme monoamine oxidase; 149 
MAO), as well as development of tricyclic antidepressants (which inhibit synaptic reuptake of 150 
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monoamine neurotransmitters), such as imipramine, to treat depression, led to the “serotonin 151 
hypothesis” of depression, in which depression is seen primarily to result from a deficit in 5-HT 152 
function (24; 25). The theory expanded to consider a role for CNS 5-HT in associated clinical 153 
affective disorders as well as regulation of mood in healthy people (25). However, this 154 
pharmacotherapeutic evidence was non-specific to serotonin, and ironically, notwithstanding the 155 
risk of oversimplifying neural bases to complex disorders, the best evidence for a major role for 156 
CNS 5-HT in control of affect has come from studies that manipulate TRP entry to the brain (26).  157 
Furthermore, whilst recent studies combining neuroimaging with administration of selective 158 
serotonin reuptake inhibitors (SSRI) have also strengthened the evidence for a role for central 5-HT 159 
in depression (27), other evidence is emerging for the importance of peripheral metabolic pathways 160 
for TRP, including roles in inflammatory processes and melatonin synthesis, underlying major 161 
depression, seasonal affective disorder and bipolar disorder (1; 11; 12; 28). 162 
Central serotonin is known to be involved in cognitive function, especially memory, 163 
attention, decision making and information processing, as well as in the processing of emotionally 164 
relevant stimuli (26; 29; 30).  However, cognition and emotion, or affect, are not entirely separable, and 165 
are often strongly interdependent (31; 32; 33).  Emotions, via their neural substrates, influence memory 166 
and attention for example, and depression and anxiety are associated with cognitive impairments 167 
and biases that can contribute to the affective disorder and its maintenance (32; 34).   168 
Effects of acute tryptophan depletion 169 
 170 
This review is mainly concerned with genetic susceptibility to effects of forms of TRP 171 
administration that may lead to increased serotonin synthesis in the brain; however, by way of 172 
comparison, and given the scientific influence, a brief overview is included of findings, and their 173 
implications, on deficits in central 5-HT induced by acute TRP depletion (ATD) methods (Young 174 
2013; Young et al. 1985).  ATD is usually induced by ingestion of amino acid loads devoid of the 175 
precursor amino acid TRP to suppress 5-HT synthesis, and can be preceded by a low-TRP diet for a 176 
few days (29). This results in a substantial (e.g. >70%) and rapid drop in plasma TRP, and 177 
TRP/LNAA ratio (>80%) that may last 4-6 hours (30; 35); similar effects have been found with a 178 
more palatable low-TRP collagen protein mixture (36), and more recently a gelatin-derived TRP-free 179 
protein/carbohydrate mixture has been used (9).  Moreover, the serotonin metabolite, 5-180 
hydroxyindole acetic acid (5-HIAA) measured in cerebrospinal fluid (CSF) declined by about one-181 
third at 12 hours, after which measurements stopped (37). ATD methods have provided the most 182 
consistent evidence for serotonergic involvement in cognition, including impairment of memory 183 
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consolidation (38; 39), and aspects of cognitive flexibility including learning (40) and decision-making 184 
(41). Moreover, evidence in animal models is persuasive of opposing effects of both ATD and TRP 185 
supplementation on brain 5-HT (6; 42; 43; 44). 186 
 In support of a key role for serotonin in affective disorders, ATD also alters emotional 187 
processing and regulation (45; 46; 47). Reducing TRP access to the brain by ATD tends to mimic the 188 
cognitive biases seen in depressed populations, such as impaired memory for, attention to, or 189 
recognition of positive vs. negative information including facial expressions (34; 48; 49).  However, 190 
positive effects of ATD on cognition, for example on decision making and focused attention have 191 
also been reported (50; 51; 52), albeit interacting with history of depression (53).  One explanation has 192 
been that serotonin may affect “hot” cognitive tasks that include an affective component, but not 193 
“cold” cognitive tasks that do not obviously involve emotional stimuli (49).   194 
Neuroimaging techniques show that activity of brain regions involved in emotion regulation 195 
such as the limbic system and prefrontal cortex is sensitive to ATD (46).  The evidence is consistent 196 
with a normally inhibitory role of serotonin on any tendency for negative emotional bias (54; 55).  197 
Importantly, family or personal history of depression, sex and at-risk genotypes, have been reported 198 
to moderate effects of ATD on brain activity to emotional stimuli (46; 47; 56). 199 
Despite a history of use of anorexigenic drugs with serotonergic agonist activity such a d-200 
fenfluramine (57), and reductions in food intake established for high doses of TRP (58), and thus an 201 
expectation that ATD might increase appetite, the few studies addressing this directly in human 202 
beings suggest little effect of ATD on appetite despite concurrent mood effects (59; 60; 61).  Two 203 
studies comparing ATD in women with Bulimia Nervosa vs. healthy controls found conflicting 204 
results (60; 62): though both studies found increased negative affect in bulimic women, only one 205 
reported increased energy intake in these women (62), although the other did find an increased desire 206 
to binge eat (60).  However, curiously, another study reported a concurrent increase in both nausea 207 
and hunger in healthy women (63). These findings also need to be considered in the context of 208 
opposing relationships between depression and appetite across patients (64). 209 
Two other behaviours that appear to be sensitive to serotonin depletion are aggression and 210 
impulsivity (33; 65).  ATD has resulted in increased aggressive behaviour in the majority of studies 211 
where measured (33), and aggressive traits have correlated with plasma levels of TRP and CSF 212 
indices of serotonin turnover (65).   However, gene by environment interactions, including stressful 213 
life events, and sex differences, are likely to moderate findings (66; 67), and a meta-analysis of 214 
associations between 5-HT function and aggression in human beings revealed only a weak negative 215 
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relationship (68).  It may be that stronger associations will be found when genetic variants 216 
influencing serotonin function, such as in enzymes involved in synthesis and metabolism, or 217 
polymorphisms in transporter systems (see below), are taken into account (69; 70). Indeed, a key 218 
criticism put forward is the observation that ATD lowers TRP quite universally across participants, 219 
and yet the behavioural effects differ considerably depending on a propensity to dysfunction of 220 
mood or emotional regulation, or poor stress coping (9). 221 
Effects of TRP administration and supplementation 222 
 223 
 In contrast to ATD, which is a research tool to investigate serotoninergic processes in human 224 
beings, and for which most effects are not beneficial, administration of TRP (and its first-stage 225 
metabolite, 5-HTP) has a long history of being studied for potential clinical benefit in depression, as 226 
well as for basic research, as a means to facilitate entry of TRP into the brain and thus elevate 5-HT 227 
synthesis and release (26; 33).  The methods can vary from intravenous administration of TRP to oral 228 
supplementation of TRP, or use of TRP-rich proteins or peptide preparations, either acutely or 229 
chronically (26; 29; 71).  It is also possible to increase the TRP/LNAA ratio, and so enhance TRP entry 230 
across the BBB, by feeding a carbohydrate-rich, very low-protein meal, since the rise in insulin 231 
removes more LNAA into surrounding tissue.  This dietary method has been shown to benefit 232 
cognitive and emotional function, and reduce the cortisol response to stress, in more stress-prone, 233 
neurotic participants (72; 73; 74; 75). This mechanism has also been suggested to underlie dietary effects 234 
on mood and performance, such as calming after high-carbohydrate meals vs. arousal after protein-235 
rich meals (76; 77).  Recently, using data from the US National Health and Nutrition Examination 236 
Survey for nearly 30,000 adults, dietary intake of TRP was found to be inversely associated with self-237 
reported levels of depression, and positively related to sleep duration (more strongly in women; 238 
adjusted for protein intake) (78).  Thus, even in complex whole diets, TRP intake appears to provide 239 
psychological benefits. 240 
TRP supplementation has been employed as a potential treatment for depression and sleep 241 
disturbance since the early 1960s (24; 79), although a Cochrane Review of 108 trials (including for 5-242 
HTP) for antidepressant effects in 2002 found that only two trials were of sufficient quality to be 243 
included (80).  Nevertheless, on that limited evidence, TRP was considered to be better than placebo 244 
in alleviating depression, at least in mild to moderately depressed people.  Moreover, for more than 245 
a decade prior to that review, the US Food and Drug Administration had banned over-the-counter 246 
sales of TRP following an outbreak in 1989 of harmful eosinophilia-myalgia syndrome in users of 247 
TRP supplements.  The cause was eventually traced to impurities in TRP supplements from one 248 
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Japanese manufacturer, after which the ban was lifted in 2001 (10; 26).  Thus, for at least 5 decades, 249 
TRP has been used pharmacologically, i.e. at daily doses sometimes well in excess of 10 times the 250 
RDA (5 mg/kg) for this essential amino acid. There was early evidence for probable enhancement of 251 
brain 5-HT function: after 50 mg/kg TRP (3.5 g per 70 kg subject) was consumed in a milk drink, 252 
plasma TRP increased 8-fold, TRP in cerebrospinal fluid (CSF) increased 6-fold after 6-8 hours, and 253 
the metabolite 5-HIAA increased almost two-fold in CSF by 8 hours, suggesting increased turnover 254 
of brain 5-HT (81).  This two-fold increase in 5-HT turnover was replicated in a later study of CSF 5-255 
HIAA changes, using 3 g and 6 g TRP, with no further increase at the higher dose, although the level 256 
was sustained for longer, i.e. 12 hours vs. 8 hours (82). 257 
 In a review of potential side effects, Fernstrom (26) concluded that such use of TRP appears 258 
to be largely safe from adverse events, although the evidence is limited and not systematic.  There 259 
are some reports of symptoms such as nausea, tremor or dizziness when high doses are used (although 260 
these are also common symptoms reported in placebo-treated subjects).  However, the greatest risk 261 
of side-effects occurs when TRP is combined with other drugs that enhance 5-HT availability, such 262 
as antidepressant serotonin selective reuptake inhibitors (SSRI) or MAO inhibitors (MAOI): then a 263 
toxic ‘serotonin syndrome’ may occur that can include hyperthermia and coma (26).  A more common 264 
effect of high doses of TRP is fatigue or drowsiness, which has led to TRP being used to aid sleep, in 265 
which case sedation is not an unwanted side-effect (26).  However, a complication of oral TRP at 266 
higher doses is that it increases release of several hormones including growth hormone, cortisol and 267 
prolactin (83) (the latter thought to indicate increased central serotonin - and dopamine - activity).  A 268 
recent study also reported that intragastric administration of 1.56 g TRP increased plasma 269 
cholecystokinin and glucagon-like peptide 1 (GLP-1), as well as slowing gastric emptying (84): 270 
although subjective appetite was not affected, it is likely that these mechanisms contribute to reduced 271 
food intake reported after higher doses of TRP (58).  Even so, food intake might be reduced merely 272 
due to TRP-induced drowsiness. 273 
There is also concern that excess metabolism through pathways such as TRYCAT could lead 274 
to high levels of neuronally active metabolites such as kynurenic acid and quinolinic acid.  However, 275 
a recent review did not find evidence for adverse side-effects via these routes, although it was 276 
acknowledged that more systematic research is needed (1).  Furthermore, it has been argued that the 277 
modest antidepressant effect of TRP loading is due to accelerated hepatic degradation of TRP in 278 
depressives, probably via stress-related neuroendocrine enhancement of the catabolic hepatic enzyme 279 
TDO (85). 280 
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As would be expected in a treatment with antidepressant potential, there is considerable 281 
evidence for beneficial effects of TRP on mood and social behaviour, and these findings have recently 282 
been reviewed (22; 33). There is some evidence that TRP can reduce aggression in schizophrenic 283 
patients (33), and reduce quarrelsomeness while increasing agreeableness in healthy participants with 284 
a tendency to irritability or aggression (22).  Thus, it has been proposed that serotonin may influence 285 
a basic drive to be social, and that modulation of serotonin can alter more complex social behaviours 286 
by affecting social behaviour along an agreeable-quarrelsome axis (33).  For example, there is evidence 287 
that TRP supplementation can promote prosocial behaviour in economic decision-making tasks (22).   288 
Somewhat counterintuitively, a more recent study, in which 1 g TRP was given 3 times per day for 289 
14 days to those with a family history of depression, found increased quarrelsomeness and reduced 290 
agreeableness (at home), but improved mood, compared to placebo (86).  This was interpreted as 291 
possibly reflecting development of more control in social interactions at home. 292 
Effects of TRP-rich protein preparations 293 
 294 
Bearing in mind such concerns about loading with high doses of TRP as the single amino 295 
acid, in recent years methods have been developed to enhance TRP availability to the brain by 296 
administering TRP-rich dietary proteins: the most published example is the whey protein α-297 
lactalbumin. The effects of this protein are usually compared to responses after ingestion of another 298 
protein, typically casein hydrolysate (another milk protein), which has lower levels of TRP but 299 
greater amounts of the competing LNAA (29). 300 
 Similarly to a high-carbohydrate meal, α-lactalbumin has been shown to enhance (or correct) 301 
serotonin function (indexed by prolactin release) and cognition, and to reduce cortisol release, in 302 
stress-prone (more anxious) participants (87; 88). Alpha-lactalbumin attenuated deficits in delayed 303 
memory in women suffering from premenstrual syndrome (89) and in recovered depressives and 304 
healthy subjects (90). This TRP-rich protein also improved perception of emotional faces with in 305 
women (91): however, effects on emotional face processing tend to be weaker than dosing with TRP 306 
alone (92). 307 
Another TRP-rich protein that has been used for research in this area is a proprietary peptide 308 
product, which is an egg white protein hydrolysate formulation that contains fewer competing 309 
LNAAs (DSM Nutritional Products Ltd., Basel).  This peptide, taken in drink form, has been shown 310 
to be more effective in raising plasma TRP/LNAA ratios than either α-lactalbumin or TRP alone (93; 311 
94).  Preliminary studies using a 12-g dose (0.66 g TRP) of this TRP-rich protein hydrolysate 312 
showed improved mood in all subjects and enhanced psychomotor and vigilance performance in 313 
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individuals more resilient to stress (93; 95).  This was supported by an fMRI study in young women 314 
(96) which found that this dose improved mood acutely as well as increasing activation of brain 315 
limbic circuitry, especially medial cingulate gyrus, during a fear induction task.  Conversely, during 316 
reward anticipation, activation of reward pathways was reduced.  Effects on resting state 317 
connectivity were in line with modulation of brain regions involved in regulation of mood.  318 
Subsequently, lower doses were found to be effective in enhancing mood and positivity in 319 
emotional processing acutely (0.13 g TRP) (97), and chronically (0.07 g TRP for 19 days) in 320 
improving aspects of mood and sleep, as well as modest benefits to cognition, in middle-aged 321 
women, relative to a casein control treatment (98). 322 
 323 
Role of genetics in moderating effects of TRP supplementation or challenge on 324 
serotonin-related behaviours 325 
 326 
Gene polymorphisms involved in metabolism of TRP and regulation of serotonin could have a 327 
substantial influence on behavioural effects of manipulations of TRP availability.  There is potential 328 
for moderation of TRP effects by polymorphisms in each of the key enzymes influencing TRP 329 
metabolism and thus serotonin synthesis, i.e. TPH1, TPH2, TDO, IDO, and also by polymorphisms 330 
of the monoamine oxidase A (MAO-A) enzyme that metabolises central serotonin (Figure 1).  331 
These various 5-HT-related polymorphisms may form an interactive system that determines the 332 
aetiology and prognosis of various forms of affective disorder (17; 99; 100; 101; 102). However, the most 333 
evidenced serotonergic genetic influence on behaviour is the 5-hydroxytryptamine transporter-334 
linked promoter region (5-HTTLPR) polymorphism of the serotonin transporter gene (SLC6A4) 335 
(103; 104). The recommended classification of 5-HTTLPR genotypes is a functional combination of 336 
variable number tandem repeats (VNTR) of short or long length of the gene promoter amplicon and 337 
single nucleotide polymorphism (SNP) variants, LA and LG, where LG is functionally equivalent to 338 
the short, and LA to the long, VNTR forms (103; 104). Effects of 5-HTTLPR genotypes are usually 339 
compared between the homozygous alleles that are either high (long variants; L/L’) or low (short 340 
variants but including LA; S/S’) expressing of mRNA for the 5-HT transporter receptor.   341 
Another important genetic factor in predicting serotonergic effects on behaviour is sex.  342 
Women are more susceptible to, and have higher heritability for, affective disorders (even allowing 343 
for sociocultural effects on presentation), may be more sensitive to stress, and tend to be more 344 
responsive to SSRI treatment (67).  Brain 5-HT synthesis rates are reportedly 50% lower in women 345 
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than men (105), and ATD causes greater lowering of mood in women than men (106).  In some studies, 346 
women also appear to be more sensitive to, or to benefit more from, TRP supplementation; indeed, 347 
some researchers chose to study women only for these reasons (97; 98).  Furthermore, sex interacts 348 
with serotonergic gene polymorphisms in several systems, including 5-HTTLPR, TPH1, TPH2 and 349 
MAO-A (67; 107), and these interactions can be further moderated by stress (108; 109; 110; 111).  Therefore, 350 
the sex of participants needs to be considered when interpreting findings in this area. 351 
 352 
TRP administration and 5-HTTLPR genotypes 353 
 354 
Only a few studies have investigated whether these 5-HT- and TRP-related genotypes alter 355 
the effects of TRP loading (or challenge or supplementation), and these appear to be limited to 356 
comparison of 5-HTTLPR genotypes: these studies are summarised in Table 1. In the earliest 357 
published study (108) to examine moderation of TRP loading by the 5-HTTLPR tri-allelic genotype, 358 
41 men and 31 women were infused intravenously with a high dose of TRP (100 mg/kg), while 359 
aspects of mood were assessed (Profile of Mood States; POMS).  Far from improving mood, this 360 
procedure generally increased negative affect, but the effects were moderated by genotype and sex: 361 
in men, only those with the high-expressing L/L’ polymorphism showed increased negative mood, 362 
whereas in women, only the L/L’ group showed no increase in negative mood.  This opposing 363 
interaction between sex and 5-HTTLPR genotype is in line with evidence based on the impact of 364 
social stressors on negative affect in adolescents (111).  However, sample sizes were small, especially 365 
in the S/S’ groups (7 men; 9 women). 366 
Using a far lower dose, and oral administration, Markus and Firk (112) examined potential 367 
interactions between acute TRP supplementation, stress and 5-HTTLPR genotype on mood, cortisol 368 
and cognition.  They hypothesised that the TRP challenge would ameliorate the effects of stress on 369 
mood and cortisol in subjects homozygous for the tri-allelic S/S’ genotype compared to those with 370 
the L/L’ genotype.  In a cross-over design, 30 student participants (16 S/S’-allele; 14 L/L’-allele; 371 
only one man in each group) received either TRP (2 x 0.4 g) or placebo (lactose), prior to a stressful 372 
challenge, with baseline and post-stress measures of mood (POMS) and salivary cortisol.  The 373 
stressor consisted of repeated unpredictable cold pressor stress (hand on a 1.5-oC cold plate) 374 
interspersed with a Serial-7 subtraction task (repeatedly subtracting 7 from a variable starting 375 
number), performed in front of a camera and researcher; errors were recorded.  The design did not 376 
include a stress-free condition, and only a single baseline measure of cortisol, so interpretation of 377 
the observed decline in cortisol after stress is difficult, as this decline is anyway typical for cortisol 378 
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during the morning.   However, neither TRP treatment nor genotype significantly altered this 379 
decline in cortisol.  Nevertheless, the stressor caused mood to deteriorate, with increases in feelings 380 
of anger, depression and fatigue, but a decrease in vigour.  A key finding of this study is that the 381 
TRP treatment reduced depression and fatigue, while increasing vigour, specifically in the S/S’ 382 
allele group only.  However, these effects were pooled across stress condition, so presumably were 383 
not significantly altered by stress (data for a pre/post-stress x genotype x treatment interaction were 384 
not presented).  Genotype also influenced performance on the subtraction task: the S/S’ group 385 
performed worse that the L/L’ group after placebo, but after TRP, performance was the same for 386 
both allele groups; again, this result was independent of stress.  Even so, pre-stress results were not 387 
presented, so stress may have contributed somewhat to the findings.  For example, the fact that the 388 
S/S’ group made more mistakes in the subtraction task under placebo may indicate that subjects 389 
with this genotype were not coping as well with the stressful aspect of the task: that this detriment 390 
was removed by TRP treatment strongly suggests it reflected suboptimal 5-HT function during a 391 
demanding task.  It is also important to note that this sample consisted of 28 women and only 2 392 
men. 393 
A subsequent report from this group (113) used the same stressor and TRP treatment to 394 
examine interactions of treatment, stress and 5-HTTLPR genotype on another measure of mood 395 
(Positive and Negative Affect Schedule; PANAS) and attentional bias (inhibitory responses) to 396 
negative emotional stimuli.  This bias was measured by reaction times to facial expressions varying 397 
in emotional valence and primed by previous stimuli of the same or opposite valence (Negative 398 
Affective Priming; NAP).  This study appears to have used the same participants as Markus and 399 
Firk (112) except excluding the two men (i.e. 28 women).  In the placebo condition, negative affect 400 
increased after stress only for the S/S’ genotype group, and furthermore this rise in negative mood 401 
was prevented by TRP treatment.  For the NAP task, there was an interaction between stress and 402 
genotype, such that S/S’ subjects showed faster responding to congruently than incongruently 403 
primed negative expressions after stress, an indicator of reduced inhibition to negative affective 404 
stimuli.  The L/L’ group showed the opposite response, suggesting that this allele may confer some 405 
resilience to effects of stress on emotional processing.  However, no effects of TRP treatment were 406 
found for this behaviour, though, as the authors point out, the study has a relatively small sample 407 
size and may be underpowered to detect three-way interactions of this sort. 408 
Subsequently, Markus, Verschoor and Smeets (114) established a larger student cohort 409 
screened for 5-HTTLPR genotype, and studied 19 female S/S’ and 23 female L/L’ homozygous 410 
allele groups, with about half of each group selected to be either high or low on restrained eating 411 
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(Three Factor Eating Questionnaire, TFEQ (115)).  This study investigated potential interactions 412 
between TRP treatment, 5-HTTLPR genotype, stress, restraint and emotional eating, in a double-413 
blind placebo-controlled crossover design.  Stress was elicited using a modified Trier Social Stress 414 
Test (116); TRP challenge was accomplished using an egg white protein hydrolysate enriched with 415 
TRP (4-g dose given as a 200-ml drink, containing 0.24 g TRP;  DSM, Delft; see above), versus a 416 
casein hydrolysate placebo (0.03 g TRP).  Blood samples were taken for amino acid analysis 90 417 
minutes after consuming the drinks, and four salivary samples were taken during the study to assess 418 
cortisol levels.  Interestingly, there was a significantly greater increase in plasma TRP/LNAA 419 
following TRP treatment for the L/L’ group (70% increase) compared to the S/S’ group (30% 420 
increase).  However, although stress resulted in a rise in cortisol, there were no significant effects of 421 
either TRP treatment, genotype or restrained eating on cortisol in this study.  Mood generally 422 
deteriorated from before to after the stress; of particular interest, the increase in anger after stress 423 
occurred in all groups except the L/L’ genotype group who had received TRP supplementation, in 424 
whom there was no change in anger following stress. 425 
Liking (pleasantness of taste) for a variety of foods of different sensory categories (sweet or 426 
savoury, low- or high-fat) was assessed using ratings of images of the foods.  Only the high-fat 427 
sweet food liking ratings showed significant effects: in the L/L’ allele group, liking for high-fat 428 
sweet foods declined following stress only when given the TRP supplement, whereas there were no 429 
significant changes to liking ratings for the S/S’ allele group.  Actual food intake was assessed by 430 
offering several of snack foods (mini chocolate bars, pretzels and nuts) both before and after stress.  431 
The only significant result was a 38% reduction in snack intake after TRP treatment (averaged 432 
across stress pre/post measures); no effects of genotype, stress or restrained eating were seen.  An 433 
overall appetite-suppressant effect of TRP may be expected, given that ATD tends to increase 434 
appetite (63), and higher doses of TRP (at least 2 g) have long been known to suppress appetite and 435 
reduce food intake by 10-20% (58); nevertheless, the dose of TRP effective here is considerably 436 
smaller (0.24 g), so the size of this effect is remarkable. 437 
There are several intriguing findings in this study, not least the weaker increase in plasma 438 
TRP/LNAA in the S/S’ subjects.  The authors point out that this difference between genotypes is a 439 
unique finding, and speculate that it may be due to increased diversion of peripheral TRP to 440 
metabolism via the kynurenine pathway, due to induction of the hepatic TDO and peripheral IDO 441 
enzymes, which are known to be stress-sensitive (14).  However, direct evidence for such a 442 
mechanism reducing the TRP/LNAA ratio in S/S’ allele subjects after TRP supplementation is 443 
lacking.  One study that measured 5-HTTLPR genotypes and administered 50 mg/kg TRP did 444 
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assess the plasma kynurenine:TRP ratio as an index of TDO activity; however, this was in male 445 
patients with alcohol use disorder, and the study did not assess behavioural effects of TRP (117). 446 
Those patients who experienced “blacked-out violent impulsive behaviour” during binge drinking 447 
showed a higher kynurenine:TRP ratio than those who did not, suggesting that less TRP would be 448 
available to the brain.  Nevertheless, no differences were reported for 5-HTTLPR genotype 449 
subgroups, although sample sizes may have been two small (9 cases, 9 alcohol-dependent controls, 450 
received oral TRP) for meaningful statistics in this pilot study, and polymorphisms in the enzymes 451 
themselves were not measured.  This may be important as there is evidence for example that the 452 
TPH1 218AA polymorphism is a risk factor for alcoholism and bipolar disorder (118).  Anyhow, this 453 
impaired effect of TRP treatment on the plasma ratio in this S/S’ group (114) may explain the lack of 454 
behavioural effects seen for this group in this study, in contrast to some effects that were specific to 455 
the L/L’ genotype.  On the other hand, the most likely explanation for a lack of stress-induced, or 456 
emotional, eating is the probability that few of the participants had emotional eating tendencies.  457 
Participants were selected on the basis of scores on the TFEQ restrained eating scale, which, unlike 458 
some items on the disinhibition or hunger scales of this questionnaire, does not explicitly assess 459 
emotional eating and is usually orthogonal to it.  We have argued previously that cognitive restraint 460 
per se is not a good predictor of stress eating tendencies (119; 120).  Furthermore, in a more recent 461 
study from this group, S/S’ allele subjects (both male and female) were shown to be more likely to 462 
eat sweet fatty foods after mild stress than L/L’ genotypes, an effect that was reduced by a sucrose 463 
preload (121).  However, in that study, there was no manipulation by TRP load.  Another study from 464 
this group investigated whether examination stress would differentially affect appetite for these two 465 
genotype groups (122): findings confirmed that the S/S’ genotype group were more likely to show 466 
stress-induced eating of sweet snacks, though again there was no manipulation of TRP.   467 
Nevertheless, the interaction between genotype, stress, emotional eating and effects of 468 
subchronic TRP supplementation was investigated in mainly female participants (99 women, 19 469 
men) asked to self-administer 3 g TRP per day for 7 days (or placebo cellulose), before undergoing 470 
an acute stress test (repeated cold pressor and serial-17 subtraction task known as the Maastricht 471 
Acute Stress Test; MAST) (123).  Changes in appetite ratings, snack intake, mood and cortisol were 472 
assessed.  Subchronic TRP treatment reduced the cortisol response to stress only in the S/S’ allele 473 
group.  Similarly, the TRP treatment resulted in significantly less stress-induced increase in anxiety 474 
only in the S/S’ group, but independently of trait neuroticism. Stress increased rated appetite, but 475 
interestingly TRP reduced this increase specifically in S/S’ subjects who also scored highly on 476 
neuroticism.  The parallels across these TRP by genotype interactions are notable.  By comparison, 477 
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the only significant finding reported for post-stress snack intake was a greater intake of sweet fatty 478 
snacks by the low neuroticism vs. the high neuroticism group, perhaps due to health concerns in the 479 
latter group. The interaction of genotype with neuroticism on stress-induced change in rated 480 
appetite is similar to the results of an earlier study in which mainly female participants with low or 481 
high trait anxiety were subjected to stress (mental arithmetic during loud noise) and treated acutely 482 
with either TRP-rich α-lactalbumin or casein (124).  Food liking and preference was assessed by 483 
responses to food images displayed via a computer program (125).  While appetite ratings increased 484 
for all groups after stress, both liking and preference for sweet foods increased specifically for high 485 
anxious participants, and these increases were prevented by α-lactalbumin treatment, implying that 486 
the increased desire for sweet food induced by stress in high-anxious participants was related to 487 
impaired 5-HT function.  However, in this study, genotypes were not measured.  Moreover, in the 488 
case of actual eating (122), it seems that other factors influenced the behaviour, although differences 489 
in timing between stress and food intake could be involved, and in this subchronic treatment design, 490 
no treatment was given on the test day.  491 
Another group also examined effects of a similar subchronic TRP treatment (2.8 g/day for 6 492 
days) on responses to stress (TSST) in relation to 5-HTTLPR genotype (126).  In this study about half 493 
the participants were female (22 women, 24 men), although sex was included as a covariate in 494 
analyses, rather than reporting interactions with sex.  There was a clear interaction between stress, 495 
genotype and treatment on salivary cortisol:  S/S’ allele subjects on placebo (cellulose) showed the 496 
largest rise in cortisol induced by the stress, supporting a stress sensitivity of this genotype, but this 497 
effect was substantially reduced by prior TRP treatment (even though no TRP was taken on the test 498 
day): the lower cortisol response in L/L’ participants was not further reduced by TRP.  However, 499 
while mood deteriorated after the stress, this was not differentially influenced either by treatment or 500 
genotype, contrary to Capello and Markus (123).  501 
Subsequently, a recent study investigated whether a similar subchronic treatment with TRP 502 
(3 g/day for 7 days) could benefit quality of sleep, and whether this might depend on 5-HTTLPR 503 
genotype (127).  Thus, this study compared effects between S/S’ allele subjects (46 women, 11 men) 504 
and L/L’ allele subjects (46 women, 8 men).  Potential effects of neuroticism were investigated 505 
using a median split of questionnaire scores into high and low neuroticism groups.  General sleep 506 
quality was assessed prior to treatment, then sleep quality after the week of treatment was measured 507 
for a further week.  Higher neurotic participants tended to report lower general sleep quality, 508 
unrelated to genotype.  However, following treatment, specifically S/S’ genotype together with 509 
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higher neuroticism was associated with poorer sleep quality for the placebo group, but with better 510 
sleep quality for the TRP-treated group. 511 
Finally, there is recent evidence of differential impact of 5-HTTLPR genotypes on mood 512 
changes during challenging tasks in the context of two intervention studies that had found beneficial 513 
effects of acute (97) and chronic (98) treatment with a TRP-rich egg-white protein hydrolysate (DSM) 514 
on mood, emotional processing and cognition in Caucasian women aged 45-65 years (128).  515 
Participants were genotyped for the tri-allelic 5-HTTLPR polymorphism, and distributions of 516 
genotypes were in accordance with Hardy-Weinberg equilibrium (allele sample sizes; acute study: 517 
SS/SLG = 11, SLG/SLGLA = 36, LALA = 13; chronic study: SS/SLG = 13, SLG/SLGLA = 36, LALA = 518 
10). 519 
We planned to compare the two homozygous groups (SS/LG [designated S/S’] vs. LALA 520 
[designated L/L’]) on behavioural outcomes; however, with several different treatment groups, cell 521 
sizes would be too small for meaningful analyses of treatment by genotype effects.  Therefore, we 522 
examined outcomes on the pretreatment baseline day, when the participants completed the same set 523 
of tests as during treatment, which allowed us to pool the outcome data for all participants within 524 
each genotype group.  The series of cognitive and behavioural tests lasted for 3.5 hours from the 525 
baseline (pre-test) mood measure to the final post-test mood measure, with one hour of rest in 526 
between, so represented a challenging and potentially ego-threatening process for the participants. 527 
Furthermore, we compared pre-test to post-test changes only in those emotions that had proved 528 
responsive to subsequent TRP supplementation treatment.  Specifically, these were well-being and 529 
fatigue in the acute study, and a positive feeling of ‘high energy’ (stimulated, buzzing, impulsive) in 530 
the chronic study (emotions were derived by factor analyses of ratings on 28 items presented on a 531 
computer, known as the Mental and Physical Sensations Scale).  For the acute study, we found that 532 
well-being declined from pre- to post-test in the S/S’ group, but not in the L/L’ group, whereas 533 
fatigue increased significantly only for the S/S’ group.  For the chronic study, ‘high energy’ mood 534 
increased from pre- to post-test for the L/L’ group, but did not change for the S/S’ group.     535 
These differences in genotypes for mood changes during challenging and potentially 536 
stressful tasks are in line with evidence that the S/S’ genotype would confer greater risk of affective 537 
disorders such as anxiety or depression, or conversely a protective effect of the L/L’ allele, in 538 
women.  Moreover, the known sensitivity of these changes in mood to TRP treatment supports 539 
mediation via changes in serotonin function. 540 
[Table 1 about here] 541 
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 542 
Conclusions 543 
 544 
The main theme emerging from the literature on TRP supplementation and genotypes is the 545 
observations of interactions between TRP and genotypes, sex and stress on changes in mood, 546 
cognition, cortisol and appetite.  It is particularly important to consider the influence of a key 547 
‘genotype’, sex.  For example, in women, the 5-HTTLPR S/S’ genotype predicts sensitivity to 548 
improvements in mood by TRP supplementation, especially during stressful challenges, whereas the 549 
L/L’ genotype tends to be protective against stress-induced mood deterioration and rise in cortisol, 550 
but may differ in sensitivity to TRP administration.  In men, if anything, the L/L’ genotype confers 551 
risk of stress-induced increases in negative affect; however, there are insufficient studies with 552 
adequate power to detect sex x genotype x stress x TRP in the literature to draw strong conclusions. 553 
Since the 5-HTTLPR genotypes may influence neurodevelopment and/or tonic 5-HT 554 
adaptive responsiveness at least as much as acute functioning of the brain serotonin system (103; 129), 555 
it would be advantageous to assess extent of early life stress and/or stressful life events, as well as 556 
personality traits predictive of affective disorders, in studies of TRP effects on behaviour.  557 
However, when measuring multiple influences on behaviour, as well as sex differences, 558 
investigators need to ensure sufficiently large sample sizes to increase the likelihood of reliable 559 
findings (107): routinely screening for genetic polymorphisms in suitable populations would be 560 
helpful. 561 
There is a need to broaden studies on the potential benefits of TRP supplementation to 562 
include a greater range of serotonin-related genotypes, including enzymes involved in key 563 
metabolic pathways (Figure 1).  This may eventually lead to clear predictions as to who is likely to 564 
benefit most from this relatively simple nutrient-based treatment.  Until then, although there is 565 
preliminary evidence that individuals with some genotypes, particularly the 5-HTTLPR S/S’ allele 566 
in women, may benefit from TRP supplementation as an aid to stress coping and emotional 567 
regulation including comfort eating, further research is needed before reliable recommendations can 568 
be made on targeted use of TRP treatment, or adjustment of dietary TRP intake, for beneficial 569 
behavioural outcomes. 570 
 571 
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Table 1: Summary of studies investigating interactions between TRP supplementation or challenge and tri-allelic 5-HTTLPR genotypes on 897 
behaviour 898 
Reference Sample Design and 
intervention 
Measures Main findings Comments 
Brummett et al. 
(2008) (108) 
Healthy adults; 
31 females, 41 
males; 54% 
Mean ±SD age 
= 33.5 ±9.1 
Single blind. 
Overnight fast. TRP 
(10 mg/kg body 
weight) i.v. infusion. 
Saline infusion day 
1, followed by TRP 
on day 2. 
Negative affect assessed 
by Profile of Mood 
States (POMS) prior to 
and 1 hr after start of 
infusion. 
Scores for Depression-
Dejection increased 3-fold 
from pre- to post-TRP 
infusion for L/L’ males, but 
did not change for S/L or 
S/S’ males.  In females, 
L/L’ scores did not change, 
but increased moderately for 
S/S’ genotypes. 
 
Small sample size for 
S/S’ groups (7 males, 
9 females). No saline 
infusion on same day 
as TRP. No 
significant effects on 
fatigue, anxiety and 
anger. 
Markus & Firk 
(2009) (112) 
28 female and 2 
male students. 
Mean ±SD age 
= 19 ±2. 
Double-blind cross-
over design. 
Overnight fast. Oral 
TRP (2 x 0.4 g) or 
lactose placebo 
capsules, then 
stressful challenge 
(cold pressor and 
Serial-7 tasks in 
front of camera).   
 
POMS at baseline and 
post-stress.  Cortisol in 
saliva. 
TRP reduced depression and 
fatigue scores, and increased 
vigour, only in S/S’ 
genotypes.  No interaction 
with pre/post-stress. 
No stress-free 
condition.  Single 
cortisol samples pre- 
and post-stress.  No 
effect of TRP or 
genotype on cortisol. 
Markus & De 
Raedt (2011) 
(113) 
28 female 
students. Mean 
±SD age = 19 
±2. 
Double-blind cross-
over design. 
Overnight fast. Oral 
TRP (0.8 g) vs. 
cellulose placebo, 
then stressful 
challenge (cold 
Negative affect priming 
(NAP) using pictures 
with positive or negative 
valence – assesses 
tendency to inhibit 
negative emotional 
information.  Positive 
TRP prevented the modest 
increase in negative affect 
seen after placebo for S/S’ 
but not L/L’ allele group.  
Stress weakened ability to 
inhibit negative information 
in S/S’ allele group but 
No stress-free 
condition.  Despite 
NAP being sensitive 
to stress and 
genotype, no effect of 
TRP on this measure. 
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pressor and Serial-7 
tasks in front of 
camera).   
and negative affect by 
questionnaire (Positive 
and Negative Affect 
Schedule; PANAS). 
 
enhanced it in L/L’ group.  
No effect of TRP on this 
measure. 
Markus et al. 
(2012) (114) 
42 female 
students (19 
S/S’, 23 L/L’). 
High or Low 
restrained eaters. 
Mean ±SD age 
= 19 ±2. 
Double-blind cross-
over design, 
counterbalanced for 
genotype and 
restraint level. TRP-
rich protein 
hydrolysate drink 
(235 mg TRP) or 
placebo (casein 
hydrolysate), then 
stress: adapted Trier 
Social Stress Test 
(TSST). 
Baseline, pre- and post-
stress measures of 
salivary cortisol (3 before 
stress, one after), mood 
(POMS), urge for food, 
snack food intake. 
No effect of TRP or 
genotype on stress-induced 
rise in cortisol.  Stress 
increased anger in both TRP 
and placebo conditions, 
except for L/L’ group who 
did not increase anger after 
TRP.  This same L/L’ group 
showed reduced liking for 
high-fat sweet foods after 
stress in the TRP condition 
only.  Overall, TRP reduced 
food intake vs. placebo 
No interactions with 
restrained eating, but 
this is not a good 
measure of emotional 
eating tendencies.  
Snack food intake 
during the study may 
have modified impact 
of TRP treatment, but 
note that L/L’ 
showed greatest 
increase in plasma 
TRP/LNAA after 
TRP treatment vs. 
placebo. 
 
Cerit et al. 
(2013) (126) 
22 females, 24 
males; approx. 
half of each 
were S/S’ or 
L/L’. Mean ±SD 
age = 20.4 ±3. 
Double-blind 
between-subjects, 
stratified by 
genotype. 
Subchronic oral TRP 
(2.8 g/day as 7 x 0.4 
g capsules taken 
morning, afternoon 
and evening) for 6 
days, then TSST on 
day 7. 
 
Anxiety and depression 
(Hospital Anxiety and 
Depression Scale; 
HADS); positive and 
negative affect 
(PANAS); tension, 
anxiety, sadness, 
annoyance by single-item 
Mood States Scale 
(MSS) 
No effects of TRP on 
mood/symptoms measures.  
Stress increased tension, 
anxiety and annoyance 
(MSS).  No interactions 
with genotype.  S/S’ group, 
not L/L’ group, showed 
higher stress-induced 
cortisol rise after placebo 
that was suppressed in TRP 
condition. 
Cortisol results 
suggest that S/S’ 
show greater stress 
responsiveness that in 
turn is reduced by 
TRP.  Cortisol AUC 
not analysed. Sex 
analysed as a 
covariate, but 
significance not 
reported.  
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Capello & 
Markus (2014) 
(123) 
99 female, 19 
male, students; 
60 in S/S’ and 
58 in L/L’ 
groups. Mean 
±SD age = 24.0 
±1.7. 
Double-blind 
between-subjects, 
stratified by 
genotype and 
neuroticism (N) trait 
(Dutch Personality 
Inventory; DPQ-N). 
Subchronic oral TRP 
(3 g/day as 2 x 0.5 g 
capsules taken 3 
times/day) for 7 
days, then stress 
(Maastricht Acute 
Stress Test) after 
lunch on day 8. 
Salivary cortisol (one 
baseline, two post-
stress), mood (POMS), 
anxiety (state scale of 
State and Train Anxiety 
Inventory), appetite 
ratings, pre- and post-
stress.  Snack food intake 
after stress. 
Stress-induced rise in 
cortisol was reduced by 
TRP only in the S/S’ group.  
TRP treatment also reduced 
the stress-induced rise in 
anxiety (STAI) only in the 
S/S’ group. Negative affect 
(POMS) was increased by 
stress but not altered by 
genotype or treatment.  For 
S/S’ only, high N subjects 
showed stress-induced 
increase in appetite after 
placebo but not after TRP.  
Curiously, low N subjects 
ate more high-fat sweet 
snacks than did high N. 
 
Relatively large 
sample but not 
enough males to 
examine sex effects.  
Parallel effects of 
TRP in S/S’ subjects 
for cortisol, anxiety 
and appetite.  Lunch 
intake, sex and body 
mass index controlled 
for by covariance.  
Avoidance of high-
fat sweet snacks in 
high N subjects may 
be related to 
health/weight 
concerns. 
Van Dalfsen & 
Markus (2015) 
(127) 
S/S’ allele 
group: 46 
women, 11 men; 
L/L’ allele: 46 
women, 8 men. 
Mean ±SD age 
= 23.9 ±1.7. 
Double-blind 
between-subjects, 
stratified by 
genotype and 
neuroticism trait 
(median split on 
DPQ-N). Subchronic 
oral TRP (3 g/day as 
2 x 0.5 g capsules 
taken 3 times/day) 
for 7 days. 
Prior to treatment: 
subjective sleep quality 
(1 month; adapted 
Pittsburg Sleep Quality 
Index, PSQI), 
neuroticism (DPQ-N), 
depression (Beck 
Depression Inventory, 
BDI), Stressful Life 
Events (SLE; Dutch Life 
Events Questionnaire).  
During treatment: Daily 
Hassles Checklist.  After 
treatment: PSQI sleep 
quality for 1 week. 
 
More neurotic participants 
had lower general sleep 
quality, unrelated to 
genotype, and also reported 
more SLE.  Following 
treatment, only S/S’ 
genotype together with 
higher neuroticism was 
associated with poorer sleep 
quality for the placebo 
group, but with better sleep 
quality for the TRP-treated 
group.  
The main effect of 
neuroticism was 
stronger when BDI 
depression was not 
accounted for as a 
covariate.  Sex and 
SLE were not 
significant covariates. 
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Figure 1 caption: 899 
This figure illustrates metabolic and other biochemical pathways in gut and blood that moderate the ability of supplementary tryptophan (TRP) 900 
to enter the brain as the precursor for synthesis of brain serotonin (5-HT), and thus to alter behaviour, especially mood, cognition and appetite.  901 
Rounded rectangles indicate enzymes involved in the various pathways.  Thus, IDO and TDO are involved in catabolism of TRP via the 902 
‘TRYCAT’ pathway, resulting in kynurenine (KYN) and then niacin formation.  This could alter the TRP/LNAA ratio and thus TRP entry into 903 
the brain, where the enzyme tryptophan hydroxylase (TPH; present as either TPH1 or TPH2) is the rate-limiting step for conversion of TRP to 5-904 
HT in serotonergic neurones. Action of 5-HT at the synapse can in turn be modified by the enzyme monoamine oxidase-A (MAO-A), and by the 905 
5-HT transporter system that has functional genetic variants in the 5-HT transporter-linked promoter region (5-HTTLPR).  Abbreviations in bold 906 
represent influences that have known functional genetic variants which may vary in their moderating effects; these in turn can interact with sex.  907 
Other abbreviations: LNAA, large neutral amino acids; IDO, indole 2,3-dioxygenase; TDO, tryptophan 2,3-dioxygenase. 908 
  909 
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